Skip to main content

Table 2 Mean change from baseline in 6MWT, BDI scores, and NT-proBNP levels after treatment with ambrisentan (ITT population): post-hoc analysis

From: Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis

Efficacy measure Time point CTD-PAH(N = 71) IPAH/HPAH (N = 50) Between-group difference$
6MWT, m (LOCF) Baseline 366.4 (60.4) 397.3 (48.1)  
Change from baseline (Week 12) 63.8 (57.4) 45.5 (69.7) −18.39
p value < 0.001* < 0.001* 0.115¥
Change from baseline (Week 24) 73.2 (84.6) 62.2 (81.9) −10.97
p value < 0.001* < 0.001* 0.478¥
BDI score (LOCF) Baseline 2.7 (1.4) 2.3 (1.5)  
Change from baseline (Week 12) −0.6 (1.1) −0.2 (1.9) 0.35
p value < 0.001§ 0.427§ 0.203
Change from baseline (Week 24) −0.4 (1.70) −0.2 (1.96) 0.19
p value 0.002§ 0.138§ 0.377
NT-proBNP, ng/L (Observed data) Baseline 1837.5 (2209.6) 1281.3 (1140.6)  
Change from baseline (Week 12) −1156.8 (1735.4) −450.3 (699) 706.49
p value < 0.001§ < 0.001§ 0.007
Change from baseline (Week 24) −1095.5 (1587.7) − 396.6 (738.5) 698.89
p value < 0.001§ < 0.001§ 0.011
  1. BDI Borg Dyspnoea Index, CTD connective tissue disease, HPAH Heritable PAH, IPAH Idiopathic PAH, ITT intent-to-treat, NT-ProBNP N-terminal pro hormone B-Type Natriuretic Peptide, 6MWT six-minute walk test
\